Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASTER: Ligelizumab Mechanism of Action in Chronic Urticaria
NCT04513548Phase 1Terminated
- Sponsor
- Novartis
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic spontaneous urticaria (CSU), Cholinergic Urticaria (CU) and Cold urticaria (CU) comparing Ligelizumab with Placebo (2 arms). Primary endpoints: Wheal and erythema size after skin prick test with ciprofloxacin and icatibant at Day 1 and Change in wheal size after challenge procedure at Week 16. Started Aug 2020; status: terminated.
02
Drugs
ligelizumab
03
Conditions
chronic spontaneous urticaria (CSU)Cholinergic Urticaria (CU)Cold urticaria (CU)
Beyond the preview
Go deeper on NCT04513548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513548.